Comparison of the data of the current work and those of the ECOG study14
| . | Current study . | ECOG study . |
|---|---|---|
| No. of patients | 402 | 657 |
| Enrollment period | August 2001 to September 2008 | December 2002 to November 2008 |
| Median age, y (range) | 43 (15-60) | 48 (17-60) |
| Median follow-up duration, mo (range) | 52.6 (3.2-105.6) | 25.2 (0.6-70.3) |
| Induction chemotherapy | ||
| Daunorubicin, mg/m2 per day | 45 vs 90 (3 days) continuous infusion | 45 vs 90 (3 days) short infusion (10-15 minutes) |
| Cytarabine, mg/m2 per day | 200 (7 days) | 100 (7 days) |
| Reinduction therapy | ||
| Timing | Day 14 | Days 12-14 |
| Regimen | Daunorubicin 45 mg/m2 per day for 2 days; cytarabine 200 mg/m2 per day for 5 days | Daunorubicin 45 mg/m2 per day for 3 days; cytarabine 100 mg/m2 per day for 7 days |
| Postremission therapy | HDAC × 4, then AD5 + 1 × 2, allogeneic HCT (intermediate- or poor-risk cytogenetics if suitable donor available; usually after the second course of HDAC) | Allogeneic HCT (intermediate- or poor-risk cytogenetics if suitable related donor available; no other post-remission therapy) OR HDAC × 2, then autologous HCT (other patients) |
| CR, % | 72.0 vs 82.5 | 57.3 vs 70.6 |
| Median OS, mo | 21.9 vs 35.2 | 15.7 vs 23.7 |
| Subgroup showing major benefits upon use of HD-DN | Intermediate-risk cytogenetic group | Intermediate-risk cytogenetic group |
| . | Current study . | ECOG study . |
|---|---|---|
| No. of patients | 402 | 657 |
| Enrollment period | August 2001 to September 2008 | December 2002 to November 2008 |
| Median age, y (range) | 43 (15-60) | 48 (17-60) |
| Median follow-up duration, mo (range) | 52.6 (3.2-105.6) | 25.2 (0.6-70.3) |
| Induction chemotherapy | ||
| Daunorubicin, mg/m2 per day | 45 vs 90 (3 days) continuous infusion | 45 vs 90 (3 days) short infusion (10-15 minutes) |
| Cytarabine, mg/m2 per day | 200 (7 days) | 100 (7 days) |
| Reinduction therapy | ||
| Timing | Day 14 | Days 12-14 |
| Regimen | Daunorubicin 45 mg/m2 per day for 2 days; cytarabine 200 mg/m2 per day for 5 days | Daunorubicin 45 mg/m2 per day for 3 days; cytarabine 100 mg/m2 per day for 7 days |
| Postremission therapy | HDAC × 4, then AD5 + 1 × 2, allogeneic HCT (intermediate- or poor-risk cytogenetics if suitable donor available; usually after the second course of HDAC) | Allogeneic HCT (intermediate- or poor-risk cytogenetics if suitable related donor available; no other post-remission therapy) OR HDAC × 2, then autologous HCT (other patients) |
| CR, % | 72.0 vs 82.5 | 57.3 vs 70.6 |
| Median OS, mo | 21.9 vs 35.2 | 15.7 vs 23.7 |
| Subgroup showing major benefits upon use of HD-DN | Intermediate-risk cytogenetic group | Intermediate-risk cytogenetic group |
HDAC indicates high-dose cytarabine (3 g/m2 every 12 hours on days 1, 3, and 5); and AD5 + 1, cytarabine (200 mg/m2 per day for 5 days) and daunorubicin (45 mg/m2 for 1 day).